Anika Days Sales Outstanding from 2010 to 2024

ANIK Stock  USD 16.04  0.58  3.49%   
Anika Therapeutics Days Sales Outstanding yearly trend continues to be quite stable with very little volatility. The value of Days Sales Outstanding is projected to decrease to 54.36. From the period between 2010 and 2024, Anika Therapeutics, Days Sales Outstanding regression line of its data series had standard deviation of  16.68 and standard deviation of  16.68. View All Fundamentals
 
Days Sales Outstanding  
First Reported
2010-12-31
Previous Quarter
78.75679519
Current Value
54.36
Quarterly Volatility
16.67610426
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Anika Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Anika Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 14.9 M, Interest Expense of 1.3 M or Selling General Administrative of 103.5 M, as well as many indicators such as Price To Sales Ratio of 3.33, Dividend Yield of 0.0 or PTB Ratio of 1.73. Anika financial statements analysis is a perfect complement when working with Anika Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Anika Therapeutics Correlation against competitors.
For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.

Latest Anika Therapeutics' Days Sales Outstanding Growth Pattern

Below is the plot of the Days Sales Outstanding of Anika Therapeutics over the last few years. It is Anika Therapeutics' Days Sales Outstanding historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Anika Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Days Sales Outstanding10 Years Trend
Slightly volatile
   Days Sales Outstanding   
       Timeline  

Anika Days Sales Outstanding Regression Statistics

Arithmetic Mean77.80
Geometric Mean76.09
Coefficient Of Variation21.43
Mean Deviation12.78
Median76.67
Standard Deviation16.68
Sample Variance278.09
Range60.0082
R-Value(0.31)
Mean Square Error271.60
R-Squared0.09
Significance0.27
Slope(1.14)
Total Sum of Squares3,893

Anika Days Sales Outstanding History

2024 54.36
2023 78.76
2022 80.9
2021 73.7
2020 67.43
2019 73.5
2018 71.84

About Anika Therapeutics Financial Statements

Anika Therapeutics investors utilize fundamental indicators, such as Days Sales Outstanding, to predict how Anika Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Days Sales Outstanding 78.76  54.36 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Anika Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Anika Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Anika Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Anika Therapeutics Stock:
Check out the analysis of Anika Therapeutics Correlation against competitors.
For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.
You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anika Therapeutics. If investors know Anika will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anika Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.51)
Earnings Share
(6.64)
Revenue Per Share
11.139
Quarterly Revenue Growth
(0.07)
Return On Assets
(0.04)
The market value of Anika Therapeutics is measured differently than its book value, which is the value of Anika that is recorded on the company's balance sheet. Investors also form their own opinion of Anika Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Anika Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anika Therapeutics' market value can be influenced by many factors that don't directly affect Anika Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anika Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anika Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anika Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.